Acorda Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 08, 2023 at 04:01 pm EDT
Share
Acorda Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 29.68 million compared to USD 31.05 million a year ago. Net loss was USD 9.38 million compared to USD 46.68 million a year ago. Basic loss per share from continuing operations was USD 7.55 compared to USD 54.01 a year ago. Diluted loss per share from continuing operations was USD 7.55 compared to USD 54.01 a year ago.
For the six months, revenue was USD 51.93 million compared to USD 53.59 million a year ago. Net loss was USD 26.21 million compared to USD 71.21 million a year ago. Basic loss per share from continuing operations was USD 21.1 compared to USD 97.33 a year ago. Diluted loss per share from continuing operations was USD 21.1 compared to USD 97.33 a year ago.
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinsonâs disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.